Yes, and day 14 was (if I remember correctly) a we

Quote:

---

Yes, and day 14 was (if I remember correctly) a week after the second and final injection of Leronlimab. So after this the patients' bodies effectively cleared the Leron, and two weeks later, at the final endpoint of the trial, they were effectively no longer being treated. Thanks to the FDA insistence that there only be two Leron treatments, the Covid trials failed.

---

With the mild/moderate Covid trial that wasn't a problem since it was only a 14 day trial. With injections on day 0 and 7 there would still be significant receptor occupancy at day 14. The problem in that trial was that the protocol didn't insist on a minimum number of symptoms to enter the trial. If you only have one symptom you would only see a symptom score change of one which is not beneficial for statistical significance in a small trial.

The severe/critical Covid trial of course is a whole other story. A 28 day trial with injections at day 0 and day 7 we would start seeing a significant drop after day 14. By day 21 there would be minor receptor occupancy and by day 28 there would be none. From the results we can see an uptick in deaths at day 21 and little better than other treatments at day 28. In severe/critical you're going to see persistent viral loads through 28 days and the cytokine storm may still exist so leronlimab would be needed until the cytokine storm subsides. Even with a viral load drop you could have elevated cytokines due to secondary damage so leronlimab may still be needed.